Proinflammatory gene polymorphisms and ischemic stroke

Current Pharmaceutical Design

Volumn 14, Issue 33, 2008, Pages 3590-3600

  Yamada, Yoshiji ^a   Ichihara, Sahoko ^a   Nishida, Tamotsu ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Association study; Cerebral infraction; Genetics; Ischemic stroke; Linkage analysis; Polymorphism

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; INTERLEUKIN 6; LYMPHOTOXIN; 5-LIPOXYGENASE-ACTIVATING PROTEIN; CARRIER PROTEIN; IL6 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MEMBRANE PROTEIN; TEICHOIC ACID; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHROMOSOME 9P; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LINKAGE ANALYSIS; MOLECULAR GENETICS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; GENETIC LINKAGE; GENETICS; STROKE;

BRAIN ISCHEMIA; CARRIER PROTEINS; HUMANS; INTERLEUKIN-6; LINKAGE (GENETICS); LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; POLYMORPHISM, GENETIC; STROKE; TEICHOIC ACIDS;

EID: 59849098293     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786848793     Document Type: Review

References (127)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-45.
2. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61.
3. Rosamond W, Flegal K, Friday G, Furie, K, Go A, Greenlund K, et al. Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: E69-171.
4. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003; 362: 1211-24.
5. Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001; 87: 129-35.
6. Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: A long-term follow-up study of Danish twins. Stroke 2002; 33: 769-74.
7. Meschia JF, Worrall BB. New advances in identifying genetic anomalies in stroke-prone probands. Curr Atheroscler Rep 2003; 5: 317-23.
8. Tournier-Lasserve E, Iba-Zizen MT, Romero N, Bousser MG. Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke 1991; 22: 1297-302.
9. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain 2000; 123: 1784-812.
10. Hademenos GJ, Alberts MJ, Awad I, Mayberg M, Shepard T, Jagoda A, et al. Advances in the genetics of cerebrovascular disease and stroke. Neurology 2001; 56: 997-1008.
11. Tournier-Lasserve E. New players in the genetics of stroke. N Engl J Med 2002; 347: 1711-2.
12. Floßmann E, Schulz UGR, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004; 35: 212-27.
13. Gulcher JR, Gretarsdottir S, Helgadottir A, Stefansson K. Genes contributing to risk for common forms of stroke. Trends Mol Med 2005; 11: 217-24.
14. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med 2001; 249: 253-61.
15. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: Morbidity and risk factors. J Intern Med 2001; 250: 382-9.
16. Humphries SE, Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: Insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004; 3: 227-35.
17. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
18. Morgan L, Humphries SE. The genetics of stroke. Curr Opin Lipidol 2005; 16: 193-9.
19. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: A family history study. Stroke 2003; 34: 1364-9.
20. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke 1992; 23: 221-3.
21. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32:280-99.
22. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, Jakobsson F, Einarsdottir E, Agnarsson U, et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet 2002; 70: 593-603.
23. Morita H, Kurihara M, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998; 18: 1465-9.
24. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004; 35: 814-8.
25. Abboud S, Karhunen PJ, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessl atherosclerosis stroke. PloS One 2007; 2: E1043.
26. Morita A, Nakayama T, Soma M. Association study between C-reactive protein genes and ischemic stroke in Japanese subjects. Am J Hypertens 2006; 19: 593-600.
27. Zee RY, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: A population-based, prospective genetic analysis. Hum Mol Genet 2004; 13: 389-96.
28. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291: 2221-8.
29. Benn M, Nordestgaard BG, Jensen JS, Tybjaerg-Hansen A. Polymorphisms in apolipoprotein B and risk of ischemic stroke. J Clin Endocrinol Metab 2007; 92: 3611-7.
30. Iacoviello L, Di Castelnuovo A, Gattone M, Pezzini A, Assanelli D, Lorenzet R, et al. Polymorphisms of the interleukin-1β gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol 2005; 25: 222-7.
31. Worrall BB, Brott TG, Brown RD Jr, Brown WM, Rich SS, Arepalli S, et al. IL1RN VNTR polymorphism in ischemic stroke. Analysis in 3 populations. Stroke 2007; 38: 1189-96.
32. Lavergne E, Labreuche J, Daoudi M, Debre P, Cambien F, Deterre P, et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 847-53.
33. Lee BC, Lee HJ, Chung JH. Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci Lett 2006; 410: 141-5.
34. Cole JW, Naj AC, O'Connell JR, Stine OC, Sorkin JD, Wozniak MA, et al. Neuroserpin polymorphisms and stroke risk in a biracial population: The stroke prevention in young women study. BMC Neurol 2007; 7: 37.
35. Morrison AC, Doris PA, Folsom AR, Nieto FJ, Boerwinkle E; Atherosclerosis Risk in Communities Study. G-protein β3 subunit and α-adducin polymorphisms and risk of subclinical and clinical stroke. Stroke 2001; 32: 822-9.
36. Kessler C, Spitzer C, Stauske D, Mende S, Stadlmuller J, Walther R, et al. The apolipoprotein E and β-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 1997; 17: 2880-4.
37. Carlsson M, Orho-Melander M, Hedenbro J, Almgren P, Groop LC. The T 54 allele of the intestinal fatty acid-binding protein 2 is associated with a parental history of stroke. J Clin Endocrinol Metab 2000; 85: 2801-4.
38. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003; 35: 131-8.
39. 1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-6.
40. Stanzione R, Di Angelantonio E, Evangelista A, Barbato D, Marchitti S, Zanda B, et al. Beta2-adrenergic receptor gene polymorphisms and risk of ischemic stroke. Am J Hypertens 2007; 20: 657-62.
41. Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: A novel risk factor for arterial ischemic stroke among young adults and children. Stroke 2007; 38: 41-9.
42. Santamaria A, Mateo J, Tirado I, Oliver A, Belvis R, Marti-Fabregas J, et al. Homozygosity of the T allele of the 46 C→T polymorphism in the F12 gene is a risk factor for ischemic stroke in the Spanish population. Stroke 2004; 35: 1795-9.
43. Freiberg JJ, Tybjaerg-Hansen A, Sillesen H, Jensen GB, Nordestgaard BG. Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 990-6.
44. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
45. Szolnoki Z, Havasi V, Talian G, Bene J, Komlosi K, Somogyvari F, et al. Lymphotoxin-α gene 252G allelic variant is a risk factor for large-vessel-associated ischemic stroke. J Mol Neurosci 2005; 27: 205-11.
46. Um JY, An NH, Kim HM. TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction. J Mol Neurosci 2003; 21: 167-71.
47. Liu J, Cheng J, Peng J, Han S, Yu L, Nie S. Effects of polymorphisms of heat shock protein 70 gene on ischemic stroke, and interaction with smoking in China. Clin Chim Acta 2007; 384: 64-8.
48. Yamada Y, Metoki N, Yoshida H, Satoh K, Kato K, Hibino T, et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 2008; 39: 2211-8.
49. Shearman AM, Cooper JA, Kotwinski PJ, Humphries SE, Mendelsohn ME, Housman DE, et al. Estrogen receptor α gene variation and the risk of stroke. Stroke 2005; 36: 2281-2.
50. Sun L, Li Z, Zhang H, Ma A, Liao Y, Wang D, et al. Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese: A multicenter case-control study in China. Stroke 2003; 34: 1617-22.
51. Pola R, Flex A, Gaetani E, Flore R, Serricchio M, Pola P. Synergistic effect of -174 G/C polymorphism of the interleukin-6 gene promoter and 469 E/K polymorphism of the intercellular adhesion molecule-1 gene in Italian patients with history of ischemic stroke. Stroke 2003; 34: 881-5.
52. Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K, et al. Genetic risk for ischemic and hemorrhangic stroke. Arterioscler Thromb Vasc Biol 2006; 26: 1920-5.
53. Lee C, Kong M. An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke. Stroke 2007; 38: 2663-9.
54. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln→Arg polymorphism: An independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002; 33: 1459-64.
55. Slowik A, Wloch D, Szermer P, Wolkow P, Malecki M, Pera J, et al. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis 2007; 23: 395-400.
56. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005; 36: 1661-5.
57. Elbaz A, Poirier O, Moulin T, Chedru F, Cambien F, Amarenco P. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. The GENIC Investigators. Stroke 2000; 31: 1634-9.
58. Shimo-Nakanishi Y, Urabe T, Hattori N, Watanabe Y, Nagao T, Yokochi M, et al. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. Stroke 2001; 32: 1481-6.
59. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005; 14: 2829-37.
60. Saito K, Nakayama T, Sato N, Morita A, Takahashi T, Soma M, et al. Haplotypes of the plasminogen activator gene associated with ischemic stroke. Thromb Haemost 2006; 96: 331-6.
61. Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF, ISGS investigators. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke 2008; 39: 1586-9.
62. Hagiwara N, Kitazono T, Kamouchi M, Kuroda J, Ago T, Hata J, et al. Polymorphism in the sorbin and SH3-domain-containing-1 (SORBS1) gene and the risk of brain infarction in the Japanese population: The Fukuoka Stroke Registry and the Hisayama study. Eur J Neurol 2008; 15: 481-6.
63. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
64. Hata J, Matsuda K, Ninomiya T, Yonemoto K, Matsushita T, Ohnishi Y, et al. Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. Hum Mol Genet 2007; 16: 630-9.
65. Havasi V, Szolnoki Z, Talian G, Bene J, Komlosi K, Maasz A, et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 2006; 29: 177-83.
66. Hsieh K, Lalouschek W, Schillinger M, Endler G, Reisinger M, Janisiw M, et al. Impact of αENaC polymorphisms on the risk of ischemic cerebrovascular events: A multicenter case-control study. Clin Chem 2005; 51: 952-6.
67. Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Boerwinkle E. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2007; 195: E76-82.
68. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-9.
69. Muñoz X, Obach V, Hurtado B, de Frutos PG, Chamorro A, Sala N. Association of specific haplotypes of GAS6 gene with stroke. Thromb Haemost 2007; 98: 406-12.
70. Herrmann SM, Funke-Kaiser H, Schmidt-Petersen K, Nicaud V, Gautier-Bertrand M, Evans A, et al. Characterization of polymorphic structure of cathepsin G gene: Role in cardiovascular and cerebrovascular diseases. Arterioscler Thromb Vasc Biol 2001; 21: 1538-43.
71. Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee RY. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: A nested case-control approach. J Thromb Haemost 2006; 4: 1718-22.
72. Kubo M, Hata J, Ninomiya T, Matsuda K, Yonemoto K, Nakano T, et al. A nonsynonymous SNP in PRKCH (protein kinase C-eta) increases the risk of cerebral infarction. Nat Genet 2007; 39: 212-7.
73. Moon KS, Lee HJ, Hong SH, Kim HM, Um JY. CYP1A1 and GSTM1/T1 genetic variation in predicting risk for cerebral infarction. J Mol Neurosci 2007; 32: 155-9.
74. Alanne M, Kristiansson K, Auro K, Silander K, Kuulasmaa K, Peltonen L, et al. Variation in the selenoprotein S gene locus is associated with coronary heart disease and ischemic stroke in two independent Finnish cohorts. Hum Genet 2007; 122: 355-65.
75. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-21.
76. Ito D, Murata M, Watanabe K, Yoshida T, Saito I, Tanahashi N, et al. C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000; 31: 936-9.
77. Baker RI, Eikelboom J, Lofthouse E, Staples N, Afshar-Kharghan V, Lopez JA, et al. Platelet glycoprotein Ibα Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood 2001; 98: 36-40.
78. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
79. Margaglione M, Celentano E, Grandone E, Vecchione G, Cappucci G, Giuliani N, et al. Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol 1996; 16: 304-9.
80. Kaneko Y, Nakayama T, Saito K, Morita A, Sato I, Maruyama A, et al. Relationship between the thromboxane A2 receptor gene and susceptibility to cerebral infarction. Hypertens Res 2006; 29: 665-71.
81. Frikke-Schmidt R, Nordestgaard BG, Schnohr P, Tybjaerg-Hansen A. Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study. Eur Heart J 2004; 25: 943-51.
82. Kim Y, Lee C. The gene encoding transforming growth factor β1 confers risk of ischemic stroke and vascular dementia. Stroke 2006; 37: 2843-5.
83. Smith NL, Bis JC, Biagiotti S, Rice K, Lumley T, Kooperberg C, et al. Variation in 24 hemostatic genes and associations with non-fatal myocardial infarction and ischemic stroke. J Thromb Haemost 2008; 6: 45-53.
84. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-4.
85. Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, Sekine A, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 2004; 429: 72-5.
86. Hagiwara N, Kitazono T, Kamouchi M, Kuroda J, Ago T, Hata J, et al. Polymorphisms in the lymphotoxin alpha gene and the risk of ischemic stroke in the Japanese population. The Fukuoka Stroke Registry and the Hisayama Study. Cerebrovasc Dis 2008; 25: 417-22.
87. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
88. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 315-25.
89. Dalmon J, Laurent M, Courtois G. The human β fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993; 13: 1183-93.
90. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
91. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-62.
92. Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: The Northern Manhattan Prospective Cohort Study. Stroke 2002; 33: 1420-3.
93. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
94. Flex A, Gaetani E, Papaleo P, Straface G, Proia AS, Pecorini G, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004; 35: 2270-5.
95. Greisenegger S, Endler G, Haering D, Schillinger M, Lang W, Lalouschek W, et al. The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. Thromb Res 2003; 110: 181-6.
96. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243-52.
97. Jenny NS, Tracy RP, Ogg MS, Luong le A, Kuller LH, Arnold AM, et al. In the elderly, interleukin-6 plasma levels and the - 174G → C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 2066-71.
98. Karahan ZC, Deda G, Sipahi T, Elhan AH, Akar N. TNF-alpha - 308G/A and IL-6 -174G/C polymorphisms in the Turkish pediatric stroke patients. Thromb Res 2005; 115: 393-8.
99. Tso AR, Merino JG, Warach S. Interleukin-6 174G/C polymorphism and ischemic stroke: A systematic review. Stroke 2007; 38: 3070-5.
100. Maeda Y, Matsumoto M, Hori O, Kuwabara K, Ogawa S, Yan SD, et al. Hypoxia/reoxygenation-mediated induction of astrocyte interleukin 6: A paracrine mechanism potentially enhancing neuron survival. J Exp Med 1994; 180: 2297-308.
101. Suzuki S, Tanaka K, Nogawa S, Nagata E, Ito D, Dembo T, et al. Temporal profile and cellular localization of interleukin-6 protein after focal cerebral ischemia in rats. J Cerebr Blood Flow Metab 1999; 19: 1256-62.
102. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26: 1393-8.
103. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76: 505-9.
104. Lohmussaar E, Gschwendtner A, Mueller JC, Org T, Wichmann E, Hamann G, et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 2005; 36: 731-6.
105. Kostulas K, Gretarsdottir S, Kostulas V, Manolescu A, Helgadottir A, Thorleifsson G, et al. PDE4D and ALOX5AP genetic variants and risk for ischemic cerebrovascular disease in Sweden. J Neurol Sci 2007; 263: 113-7.
106. Meschia JF, Brott TG, Brown RD Jr, Crook R, Worrall BB, Kissela B, et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol 2005; 58: 351-61.
107. Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: A nested case-control approach. Stroke 2006; 37: 2007-11.
108. Kaushal R, Pal P, Alwell K, Haverbusch M, Flaherty M, Moomaw C, et al. Association of ALOX5AP with ischemic stroke: A population-based case-control study. Hum Genet 2007; 121: 601-7.
109. Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease 2005. Stroke 2006; 37: 288-90.
110. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 282-4.
111. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-43.
112. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91:120-6.
113. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316: 1488-91.
114. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007; 316:1491-3.
115. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
116. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-53.
117. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-41.
118. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316: 1341-5.
119. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-6.
120. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008; 40: 217-24.
121. Schunkert H, Götz A, Braund P, McGinnis R, Tregouet DA, Mangino M, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 2008; 117: 1675-84.
122. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 2008; 17: 806-14.
123. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: Identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67: 3963-9.
124. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15: R17-29.
125. Yamada Y. Identification of genetic factors and development of genetic risk diagnosis systems for cardiovascular diseases and stroke. Circ J 2006; 70: 1240-8.
126. Damani SB, Topol EJ. Future use of genomics in coronary artery disease. J Am Coll Cardiol 2007; 50: 1933-40.
127. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. JAMA 2005; 293: 2245-56.